Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens
Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority platform partner for TuneLab workflows,” said Pat Lorton, Schrödinger’s software chief. The deal comes as drugmakers ramp up AI efforts to speed candidate identification and detect safety concerns earlier—a push gaining momentum amid regulatory pressure to reduce animal testing. LiveDesign aids chemists in designing compounds and forecasting properties like absorption and distribution, key to understanding how drugs enter and move through the body. Schrödinger plans to launch TuneLab to current LiveDesign users in Q1, expanding to new clients in Q2, said Karen Akinsanya, the company’s chief strategy officer. Lilly expects broader adoption to improve the models: “More biotechs using the models means more diverse training data,” noted Aliza Apple, global head of Lilly TuneLab.
